VBI Vaccines Inc. operates as a biopharmaceutical company in the United States. It develops eVLP vaccine platform that allows for the design of enveloped (“e”) virus-like particle vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. It is also developing a thermostable technology platform that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. The company was formerly known as Paulson Capital (Delaware) Corp and changed its name to VBI Vaccines Inc. in July 2014. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
222 Third Street
Cambridge, MA 02142
Founded in 2006
VBI Vaccines Inc Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:30 PM
Jan 6 15
VBI Vaccines Inc Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:30 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Jeff Baxter, Chief Executive Officer, President and Director.
VBI Vaccines Inc Presents at Equities.com Small-Cap Stars Conference, Dec-18-2014 12:45 PM
Dec 9 14
VBI Vaccines Inc Presents at Equities.com Small-Cap Stars Conference, Dec-18-2014 12:45 PM. Venue: NASDAQ MarketSite, New York, New York, United States. Speakers: Jeff Baxter, Chief Executive Officer, President and Director.
Andrews & Springer LLC Files Class Action Lawsuit on Behalf of Legacy Shareholders of VBI Vaccines, Inc
Nov 27 14
Andrews & Springer LLC announced that it has filed a securities class action lawsuit on behalf of legacy shareholders of Paulson Capital Corp. (now referred to as VBI Vaccines Inc.) who held shares on October 11, 2013 and were eligible to vote at the Company's Annual Meeting of Shareholders held on November 8, 2013. This lawsuit was filed in the United States District Court, Southern District of New York, Case No. 14-cv-9435. Paulson Capital Corp. was once a publicly-traded financial services holding company that operated through its sole subsidiary Paulson Investment Company. According to the lawsuit, PCC issued materially false and misleading information to investors. On October 18, 2013, the Company filed a Definitive Proxy Statement on Schedule 14A (the October Proxy Statement) with the U.S. Securities and Exchange Commission and solicited votes from shareholders necessary to approve a certain restructuring transaction. Among other things, the October Proxy Statement asked PCC shareholders who held shares as of October 11, 2013 to vote on a transaction that would, among other things, spin off certain legacy assets of PCC and PIC into a Liquidating Trust for the benefit of Legacy Shareholders. The October Proxy Statement set October 11, 2013 as the record date for a shareholder meeting that was scheduled to take place on November 8, 2013. PCC represented to Legacy Shareholders that the Trust Assets included, among other things, a 25% equity interest in PIC, underwriter warrants, trading and investment securities, cash, accounts receivable and an insurance policy on the life of Chester L.F. Paulson, the founder of PIC. Collectively, the Trust Assets were valued at approximately $16.6 million. Legacy Shareholders overwhelmingly voted in favor of the Restructuring Transaction and the formation of the Liquidating Trust at the meeting of shareholders held on November 8, 2013.